450 Participants Needed

Diagnostic test for Traumatic Brain Injury

Recruiting at 2 trial locations
CD
Overseen ByCarey D Balaban, PhD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This study will establish the capability of a suite of conventional tests and the Neurolign Dx_100 I-PAS goggle system to reliably and objectively detect mTBI in an acute setting when comparing individuals with mTBI to controls with minor injuries in a similarly stressful environment.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

How is the Neurolign Dx_100 I-PAS goggle system treatment different from other treatments for traumatic brain injury?

The Neurolign Dx_100 I-PAS goggle system is unique because it uses eye-tracking technology to quickly assess brain function after a head injury, which can help in diagnosing traumatic brain injuries. This approach is different from traditional methods as it provides a rapid, objective measure of brain function changes, potentially aiding in faster decision-making for treatment.12345

Who Is on the Research Team?

CD

Carey D Balaban, PhD

Principal Investigator

University of Pittsburgh

Are You a Good Fit for This Trial?

This trial is for individuals who have recently experienced a mild traumatic brain injury (mTBI), such as a concussion, and are within 10 days of the incident. They must show specific symptoms but be relatively stable (Glasgow Coma Scale=13-15). A control group with minor injuries but no mTBI will also participate. Excluded are those with severe speech issues, certain psychiatric or neurological disorders, pregnant women, significant past head trauma, or hearing and balance disorders.

Inclusion Criteria

I had a concussion within the last 10 days with specific symptoms and a clear injury cause.
Control group: Participants with minor, non-surgical injuries not requiring hospital admission and no history of mTBI will be recruited from the same study sites

Exclusion Criteria

I have had a serious head injury with significant symptoms or findings.
I have had a brain or central nervous system tumor.
I have had conditions affecting my hearing or balance.
See 5 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks
1 visit (in-person)

Baseline Assessment

Participants undergo a comprehensive assessment battery including vestibular/oculomotor, cognitive, and symptom domains using standardized tests

1 day
1 visit (in-person)

Follow-up

Participants are monitored for changes in symptoms and neurocognitive performance at multiple time points post-injury

4-6 weeks
3 visits (in-person)

Control Group Assessment

Control participants complete a single visit with the same assessments as the mTBI group

1 day
1 visit (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • Standardized Instruments and Neurolign Dx_100 I-PAS goggle system
Trial Overview The study tests how well traditional assessments and the Neurolign Dx_100 I-PAS goggle system can identify mTBI in an emergency setting by comparing results from injured participants to those without brain injuries.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Mild Traumatic Brain Injury ParticipantsExperimental Treatment1 Intervention
Group II: Control ParticipantsActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Carey Balaban

Lead Sponsor

Trials
1
Recruited
450+

Uniformed Services University of the Health Sciences

Collaborator

Trials
130
Recruited
91,100+

University of Miami

Collaborator

Trials
976
Recruited
423,000+

United States Naval Medical Center, San Diego

Collaborator

Trials
110
Recruited
24,200+

Published Research Related to This Trial

The Traumatic Brain Injury Endpoints Development (TED) Initiative is a collaborative 5-year project aimed at improving clinical trials and treatment for traumatic brain injury (TBI), involving key stakeholders like the FDA and various research organizations.
In its first 18 months, TED has made significant progress, including engaging with the FDA on TBI biomarkers, advancing neuroimaging tools, and creating a comprehensive dataset to standardize measures across major TBI studies, all aimed at accelerating the approval of effective therapies.
The Traumatic Brain Injury Endpoints Development (TED) Initiative: Progress on a Public-Private Regulatory Collaboration To Accelerate Diagnosis and Treatment of Traumatic Brain Injury.Manley, GT., Mac Donald, CL., Markowitz, AJ., et al.[2021]

Citations

A Battery of Easily Accessible, Simple Tools for the Assessment of Concussion in Children. [2021]
The King-Devick test for sideline concussion screening in collegiate football. [2022]
King-Devick concussion test performs poorly as a screening tool in elite rugby union players: a prospective cohort study of two screening tests versus a clinical reference standard. [2020]
Portable video-oculography device for implementation in sideline concussion assessments: a prototype. [2020]
The Traumatic Brain Injury Endpoints Development (TED) Initiative: Progress on a Public-Private Regulatory Collaboration To Accelerate Diagnosis and Treatment of Traumatic Brain Injury. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security